Bibliographic detailsPorter C A, Rifkin R M. Clinical benefits and economic analysis of pegylated liposomaldoxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone inpatients with newly diagnosed multiple myeloma. Clinical Lymphoma and Myeloma 2007; 7(Supplement 4): S150-S155
StatusThis is an economic evaluation that meets the criteria for inclusion on NHS EED.
Indexing statusSubject indexing assigned by NLM
Index termsAdult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; derivatives /economics; Dexamethasone /administration & dosage; Disease Progression; dosage /adverse effects /adverse effects /adverse effects /adverse effects /analogs & derivatives /economics /economics /economics; Doxorubicin /administration & dosage; Female; Health Resources /utilization; Humans; Length of Stay /economics; Liposomes; Male; Middle Aged; Multiple Myeloma /diagnosis /drug therapy; Outcome Assessment (Health Care); Polyethylene Glycols /administration & dosage; Survival Rate; Time Factors; Treatment Outcome; Vincristine /administration & dosage